Medication compliance

These studies suggest that behavioral treatment strategies, such as CRA and CM, can be effective alone and as adjuncts to pharmacotherapy. Whether the emphasis is on abstinence, treatment retention, or medication compliance, the results of studies on behavioral approaches are promising. 

Encourage medication compliance with viral hepatitis treatments to increase sustaining virologic response. 

Emphasize the importance of limiting drug misadventures and ensuring medication compliance with the therapeutic regimen to maximize desired outcomes and minimize adverse events. 

Evaluate whether the patient is a candidate for finishing out his or her course of parenteral treatment on an outpatient basis. If so, the importance of close medical followup and medication compliance should be stressed to the patient and his or her family. 

Fenton, W. S., Blyler, C. R. Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia empirical and clinical findings. Schizophr. Bull, 23, 637-51. 

Ziguras, S. J., Klimidis, S., Lambert, T. J. R. Jackson, A. C. (2001). Determinants of anti-psychotic medication compliance in a multicultural population. Community Ment. Health J., 37(3), 273-83. 

Patients respond variably to the more than 20 FDA-approved antidepressants Only 60-70% of patients show significant response to any specific antidepressant, and there is no predictor of response to those drugs. Thus, the development of novel therapies should be geared to solve two important issues in treatment treatment resistance or refractoriness to current antidepressants, and medication compliance. 

Information regarding pathogenic factors and the importance of medication compliance should be conveyed to patients. 

Lloyd, A., Horan, W., Borgaro, S.R., Stokes, J.M., Pogge, D.L., and Harvey, P.D. (1998) Predictors of medication compliance after hospital discharge in adolescent psychiatric patients. / Child Adolesc Psychopharmacol 8 133-41. 

Olanzapine. An open trial of olanzapine monotherapy in youths with BPD showed that treatment improved mania, psychosis, depression, and aggression (Frazier et ah, 2001). Olanzapine was well tolerated and medication compliance was excellent. Weight gain was the most significant side effect (mean weight gain of 5 2.3 kg). 

Kelly GR, Scott JE, Mamon J Medication compliance and health education among outpatients with chronic mental disorders. Med Care 28 1181-1197, 1990... 

Hunt GE, Bergen J Bashir M (2002). Medication compliance and comorbid substance abuse in schizophrenia impact on community survival 4 years after relapse. Schizo-prenia Research, 54, 253-64... 

Weiss RD, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance abuse disorder. J din Psychiatry 1998 59 172-174. 

Currently, Ritalin remains a Schedule II substance, because the DEA believes continued increases in the medical prescription of these drugs without the appropriate safeguards to ensure medication compliance and accountability can only lead to increased stimulant abuse among U.S. children. 40... 

Freyhan, F. A. (1980, December). Medication compliance. International Committee for Prevention and Treatment of Depression Bulletin, p. 3. 

The most important action is to ensure that the client receives appropriate pharmacological treatment. One of the main problems in schizophrenia is lack of medication compliance. This is often caused by lack of client collaboration, often explained by the intrinsic pathological characteristics of the disease itself. Both typical and atypical depot antipsychotics formulations are available. Depot preparations are typically administered by intramuscular injection every 1-4 weeks. This may be of great advantage in patients with poor compliance. 

Mr AP also states that due to the large tumour pressing on my food pipe, he is currently having difficulty swallowing tablets. What alternative formulations could you suggest in order to facilitate medication compliance in this case ... 

Control of medical compliance in patients under long-term therapies (antihypertensive drugs, antipsychotics, etc.). 

In utilizing the collaborative model in the management of bipolar disorder, as well as depression, the psychotherapist supports the inherent coping skills of the patient, assesses progress and resistance, and tracks medication compliance. The psychotherapist can then inform the psychiatrist of any changes that have occurred and/or are required, and vice versa, thereby resulting in a more comprehensive and quality-driven level of care. 

The therapist should realize that the patient will often have poor medication compliance, hoarding, and control issues. 

The limited literature on families and psychotropic medications comes from families coping with serious mental illness. As early as the 1970s, researchers interested in schizophrenia began looking at the effects of medication not only on the schizophrenic patient but also on the family. In addition, they looked at the impact of family therapy on the patient s medication compliance (McFarlane, Dixon, Lukens, Lucksted, 2002 Sprenkle, 2003). 

Both therapy and medication compliance can improve when the family therapist and physician have a collaborative alliance with the family, not simply the patient, and can manage the varying responses of family members over time to the patient, the illness, and the medication. 

In clinical practice, one caveat in considering the applicability of the outcome research is the question of whose goals are being measured. Different members of the treatment system may have different goals. The family may want specific symptom amelioration. For example, family members may want the patient to be less agitated or more able to perform the daily tasks of family life. The physician may want better medication compliance or major clinical outcomes such as reductions in psychopathology and increases in functioning. The patient may just want to be left alone. 

Bluml BM. Definition of medication therapy management development of professionwide consensus. JAPhA 2005 45 566-572. Bond W, Hussar D. Detection methods and strategies for improving medication compliance.Am J Hosp Pharm 1991 48 1978-1988. 

To examine the relation between adverse effects profiles, study retention, and treatment outcomes in alcohol-dependent individuals receiving naltrexone for relapse prevention, 92 subjects had their adverse effects monitored weekly and categorized as either neuropsychiatric or gastrointestinal (3). The neuropsychiatric adverse effects had little effect on medication compliance but reduced the length of study retention. In contrast, the gastrointestinal adverse effects significantly affected medication compliance but not study retention. 

The risk factors for naltrexone-induced nausea have been studied in 120 alcohol-dependent patients in an open trial (14). After 5-30 days of abstinence, they received a bolus dose of naltrexone 25 mg followed by 50 mg/day for 10 weeks. Moderate to severe nausea was reported in 15%. The risk of nausea was significantly predicted by poor medication compliance, intensity of drinking during... 

Dubbert PM, King A, Rapp SR, Brief D, Martin JE, Lake M. Riboflavin as a tracer of medication compliance. J Behav Med 1985 8(3) 287-99. 

---